2024-510651-35-00招募中2 期
Diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- FAPI-74-PET/CT has a 70 % sensitivity in detecting metastathic lymph nodes
研究概览
简要总结
To assess the accuracy of 18F-FAPI-74 PET/CT in detection of local lymph node metastasis in patients with primary colon cancer
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Patients with primary colon cancer with suspicion of mesenteric lymph node metastases in computed tomography before primary cancer operation
- •Patients with primary colon cancer with potentially curable metastases
- •Patients with suspected metastasis or local recurrence in computed tomography and/or elevated carcinoembryonic antigen (CEA) in cancer surveillance
- •WHO performance score 0-2
- •Patient signs informed consent form after receiving written information
排除标准
- •Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included
- •Patient is not able to understand purpose of study
- •Medical conditions prohibiting whole body PET-CT
结局指标
主要结局
FAPI-74-PET/CT has a 70 % sensitivity in detecting metastathic lymph nodes
FAPI-74-PET/CT has a 70 % sensitivity in detecting metastathic lymph nodes
次要结局
未报告次要终点
研究者
Saila
Scientific
Turku University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
FAPI PET/CT for Lymph Node Staging in Colorectal CarcinomaColorectal CancerNCT05209750The Netherlands Cancer Institute30
进行中（未招募）
2 期
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.Prostate CancerNCT04655365CHU de Quebec-Universite Laval50
招募中
不适用
Evaluation Using FAPI-PET Targeting Cancer-associated FibroblastsNeoplasmsNCT05442151Tadashi Watabe200
招募中
不适用
18F-FAPI PET/CT in Patients With Various Types of CancerCancerNCT05810324Jilin University500
已完成
不适用
A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma18F-FAPIPancreas AdenocarcinomaSystemic TreatmentPathologic ResponseNCT06277206Zhejiang University59